Mesothelioma Types

Pleural malignant mesothelioma, genetic susceptibility and asbestos exposure.

Mutation Research: Fundamental & Molecular Mechanisms of Mutagenesis; Dec2005, Vol. 592 Issue 1/2,

Pleural malignant mesothelioma (MM) is a rare but extremely aggressive cancer. The limited impact of standard therapeutic treatments on survival rates makes the identification of factors that increase the individual risk a leading priority. The high proportion of cases explained by exposure to asbestos has guided intervention policies to an effective ban of this compound from our environment. However, MM cannot be solely attributed to this agent, and the role of predisposing factors and their interaction with asbestos exposure is increasingly studied. The role of mEH, GSTM1, GSTT1, NAT2, and CYP1A1 genotypes in modulating susceptibility to MM was examined in a case-control study of 80 subjects with a confirmed diagnosis of MM and 255 controls. Subjects with low mEH activity showed a significantly increased risk of MM (OR, 2.51; 95% CI, 1.11–5.68). The association was stronger in the group with low asbestos exposure (OR, 7.83; 95% CI, 0.98–62.60). A significant increased risk of MM was also found in NAT2 fast acetylators (OR, 1.74; 95% CI, 1.02–2.96). The presence of synergisms between genotypes, i.e., mEH and NAT2 (LRT for heterogeneity p <0.023), mEH and GSTM1 (LRT p <0.061), and NAT2 and GSTM1 (LRT p <0.049), combined with the interaction observed with exposure to asbestos, suggests the presence of gene–environment and gene–gene interactions in the development of MM, although the size of the study group does not allow to draw clearcut conclusions. Since genetic polymorphisms can also modify the extent of genetic damage occurring in subjects exposed to carcinogens, we measured the frequency of micronuclei in peripheral blood lymphocytes of a subgroup of MM cases. The limited number of cases (28) did not allow to observe significant effects. In conclusion, these results strengthen the hypothesis that individual susceptibility to MM can be modulated by the interaction between polymorphic genes involved.

To receive a FREE information packet, please fill out the following form (U.S. only please):

Name:
Phone Number:
E-mail:
Street Address:
City, State, Zip:
Comments or Questions:
**(Packet includes information on treatment, clinical trials, cancer links, how to access legal and financial resources, and frequently asked legal questions with answers provided by The David Law Firm, P.C.). By filling out the above form you consent to being contacted by The David Law Firm regarding potentially retaining legal services.

This website is sponsored by Jonathan David* of The David Law Firm. The David Law Firm is located in The Woodlands, Texas (Greater Houston Area) and can be reached toll free at 1-800-998-9729 for more information on mesothelioma. Jonathan David is not a medical doctor. The information on these pages is for the education of mesothelioma patients and their families regarding potential medical and legal options. Patients are advised to consult with a medical doctor. * Licensed by the Supreme Court of Texas.